-

Human Longevity Announces the Acquisition of DoctorsForMe

Clients now have access to Massachusetts General Hospital physician network through DoctorsForMe to help treat disease and support long-term health

SAN DIEGO--(BUSINESS WIRE)--Human Longevity, Inc., an innovator in providing data-driven health intelligence and precision health to physicians and patients, announced today the acquisition of DoctorsForMe, Inc. The acquisition now allows clients of Human Longevity to access world-class physicians and services of Mass General, well trusted by patients worldwide as one of the best hospitals in the world.

David Karow, MD, PhD, President and Chief Innovation Officer of Human Longevity, commented, "DoctorsForMe uses Big Data and AI technologies to match a patient with a doctor that perfectly matches the patient’s specific need. The acquisition enables Human Longevity to provide a complete health intelligence solution for our clients from early disease detection to personalized treatment, all with the goal of living a longer, healthier life.”

ABOUT HUMAN LONGEVITY

Human Longevity provides unparalleled, precision health analytics to individuals through the Health Nucleus™ in La Jolla, CA. The Health Nucleus provides an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. This is provided via a multi-modal approach, integrating data from an individual’s whole genome, brain and body imaging via MRI, cardiac CT calcium scan, metabolic tests and more, using machine learning and artificial intelligence.

Contacts

Debbie Feinberg, VP of Marketing
Human Longevity, Inc.
858-864-1058
dfeinberg@humanlongevity.com

Human Longevity, Inc.


Release Summary
Human Longevity clients now have access to Massachusetts General Hospital physician network through DoctorsForMe to help support long-term health.

Contacts

Debbie Feinberg, VP of Marketing
Human Longevity, Inc.
858-864-1058
dfeinberg@humanlongevity.com

Social Media Profiles
More News From Human Longevity, Inc.

Human Longevity Invests in SOLIUS to Improve Consumer Health by Mitigating Vitamin D Deficiency In US

SAN DIEGO--(BUSINESS WIRE)--Human Longevity, Inc. (HLI) a pioneer and leader in the delivery of data-driven, predictive, precision health intelligence to clients, today announced an investment in SOLIUS made via its corporate venture fund. The SOLIUS technology stimulates the production of vitamin D in the skin using a narrow spectrum of ultraviolet B (UVB) light. Vitamin D has a wide range of impact on systemic health and supports physical, mental and immune function. SOLIUS delivers safe and...

Human Longevity Oncology Division Sold to NeoGenomics for $37 Million

SAN DIEGO--(BUSINESS WIRE)--Human Longevity to focus entirely on longevity, extending the healthy, high-performance human lifespan and grow domestically and internationally....
Back to Newsroom